VISCHER AG advises Polyphor AG on the deal. Walder Wyss advises Enbiotix Inc. on this transaction.
Polyphor (SIX: POLN) and EnBiotix Inc., a privately held late clinical-stage rare disease company currently focused on products for rare, chronic respiratory diseases, have signed a merger agreement pursuant to which Polyphor acquires all of the outstanding capital stock of EnBiotix in exchange for shares of Polyphor common stock.
EnBiotix also acquires Inhaled Murepavadin at an agreed valuation of USD 10m in exchange for 2’599’655 of common shares of EnBiotix. The completion of merger will create a late stage clinical development company with two clinical programs in cystic fibrosis.
EnBiotix is a late clinical-stage rare disease company currently focused on therapies for cystic fibrosis, non-CF bronchiectasis, and non-tuberculosis mycobacterial infections, a $15 billion global market.
Polyphor is a clinical stage, Swiss biopharmaceutical company leading the research and development of a new mechanism of action in solid tumors, CXCR4 inhibition, for combination treatment in oncology.
The Vischer team was led by Matthias Staehelin (Picture) with Christian Wyss, David Jenny, and Luzius Zumstein (all Corporate/M&A), Marc Prinz (Employment) and Nadia Tarolli (Taxes).
The Walder Wyss team was led by Alexander Gutmans (Partner, Corporate/M&A and Venture Capital) and included Alex Nikitine (Partner, Corporate/M&A), Michelle Bruni (Senior Associate, Corporate/M&A and Tax), Daniel Dedeyan (Counsel, Banking and Finance) and Karina Tschon (Associate, Corporate/M&A and Venture Capital).
Involved fees earner: David Jenny – VISCHER AG; Marc Prinz – VISCHER AG; Matthias Staehelin – VISCHER AG; Nadia Tarolli – VISCHER AG; Christian Wyss – VISCHER AG; Luzius Zumstein – VISCHER AG; Michelle Bruni – Walder Wyss Ltd.; Daniel Dedeyan – Walder Wyss Ltd.; Alexander Gutmans – Walder Wyss Ltd.; Alex Nikitine – Walder Wyss Ltd.; Karina Tschon – Walder Wyss Ltd.;